Dotmatics Informatics Selected to Enhance Collaborative Research at Moulder Center for Drug Discovery

BISHOPS STORTFORD, England--(BUSINESS WIRE)--Dotmatics Limited, a leading provider of informatics solutions to the pharmaceutical and biotechnology industries, today announced that The Moulder Centre for Drug Discovery Research at Temple University have licensed Dotmatics’ suite of solutions to boost their drug discovery research efforts.

“After a thorough review of the commercially available software packages for sharing and exploiting the fruits of drug discovery research, it became clear that the Dotmatics platform represented not only the best configuration, but also the most comprehensive package available”

The Dotmatics platform is an integrated suite of software specifically designed to maximise efficiency in data transfer between research institutes, collaborators and CROs.

"After a thorough review of the commercially available software packages for sharing and exploiting the fruits of drug discovery research, it became clear that the Dotmatics platform represented not only the best configuration, but also the most comprehensive package available" said Dr. Magid Abou-Gharbia, Associate Dean for Research and Director of the Moulder Center. "In building our capacity at the Moulder Center for Drug Discovery Research we are focused on efficiently generating research data using a host of technologies and tools. The combination of Browser, Vortex and StudiesNotebook are key solutions which will allow our scientists to quickly triage, integrate and analyze data from multiple sources, speeding the pace and efficiency of research. These advantages afford our scientists increased opportunity to improve the health of patients through the discovery of new therapeutic agents."

The migration of The Moulder Center for Drug Discovery Research's legacy database to the Dotmatics platform will have a positive and dramatic impact on research workflow. Dr. Abou-Gharbia continued “Researchers at our center will benefit from the advanced data querying, analysis and reporting tools provided by this high end informatics platform. In addition, the secure web-based deployment of Dotmatics software will allow our external collaborators to easily access their data while maintaining safeguards against the release of data from unrelated programs. Our adoption of the Dotmatics system provides The Moulder Center with cutting edge Cheminformatics and database capabilities.”

About Dotmatics

At the forefront of innovation, Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile pharmaceutical, biotechnology, chemical industries and academia. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organizations, from discovery research to development to early manufacturing. The web-based knowledge solutions dramatically improve the way scientific data is queried, managed and shared within and across organizations. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, screening data management, SAR analysis, reporting, and visualization. A privately owned company, Dotmatics was founded in 2005 and is headquartered in the UK.

About The Moulder Center

The Moulder Center for Drug Discovery Research was established in 2008 as a multidisciplinary drug discovery research hub in Philadelphia’s Temple University School of Pharmacy. Equipped with unique capabilities and experienced scientists/researchers, the Center is actively pursuing collaborative research opportunities within Temple University and with external collaborators in the academic community, as well as industrial partners both in the U.S. and abroad. The Moulder Center is unique in that it is the only fully integrated academic drug discovery center focusing on a wide range of diseases and disorders. The Center is led by its founding director, Dr. Magid Abou-Gharbi, who has over 26 years of pharmaceutical industry experience as Senior Vice President of Discovery Research at Wyeth Pharmaceutical. On the web at http://moulder.temple.edu/.